Given that LOX-1 is a multiligand and multifunctional receptor underlying cardiovascular dysfunction and ASCVD [92,93,94,95,96,105], a therapy targeting LOX-1 is promising as a treatment for atherosclerosis and vasculopathy [131]. Here, OLR1 is linked to vascular disorder.